3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
66
Myelodysplastic Syndromes
38
Leukemia, Myelomonocytic, Chronic
26
Leukemia
14
Myeloproliferative Disorders
10
Recurrence
7
Lymphoma
7
Hematologic Neoplasms
7
Neoplasms
6
Primary Myelofibrosis
5
Multiple Myeloma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm, Residual
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Glioblastoma
2
Carcinoma, Renal Cell
2
Anemia, Refractory, with Excess of Blasts
2
Interventions
Dexamethasone
4
ruxolitinib
2
pomalidomide
2
daratumumab
2
Tacrolimus
2
Mycophenolic Acid
2
Lenalidomide
2
Cyclophosphamide
2
Bortezomib
2
sonidegib
1
ricolinostat
1
ponatinib
1
nirogacestat
1
fludarabine phosphate
1
fludarabine
1
dacetuzumab
1
Vorinostat
1
Stem Cell Transplantation
1
Remifentanil
1
Quality of Life
1
Methotrexate
1
Mesna
1
Melphalan
1
KW-2478
1
Hsp90 inhibitor KU757
1
Filgrastim
1
Electrocardiography
1
Cyclosporine
1
Clinical Laboratory Techniques
1
CPI-0610
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hematologic Diseases
×
Azacitidine
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled